salmeterol xinafoate/fluticasone propionate

DRUG2 trials

Sponsors

GlaxoSmithKline, Novartis Pharmaceuticals

Conditions

Asthma

Phase 3

A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma

CompletedNCT02554786

Novartis PharmaceuticalsAsthma

Start: 2015-12-29End: 2019-06-28Updated: 2020-03-05

Phase 4

Study In Asthma Control

TerminatedNCT00273026

GlaxoSmithKlineAsthma

Start: 2004-11-08End: 2006-03-28Target: 680Updated: 2018-03-21

Related Papers

Mometasone/indacaterol demonstrates similar efficacy in men and women: pooled analyses of PALLADIUM and IRIDIUM studies

2021-09-05

One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies

BMJ Open Respiratory Research2021-08-017 citations

Effect of indacaterol/mometasone on lung function in adolescents versus overall patient population: PALLADIUM study

2020-09-07

Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study.

2020-07-0935 citations

P224 Efficacy and long-term safety of QMF149 (indacaterol acetate/mometasone furoate) versus mometasone furoate and versus salmeterol xinafoate/fluticasone propionate in patients with inadequately-controlled asthma: The PALLADIUM study

2019-11-12